Connecting patients, doctors and treatments.
We founded Inphena Norge AS with base in the Oslo Science Park
Initiated two R&D projects
On the market
We have brought products on the market in Denmark and Norway
License agreement with Adalvo
Start of DAM program in Norway with the Norwegian government
Expansion into MENA and GCC
Long Term Agreement with UNICEF
Signed major outlicensing agreement for one of our products, with a large european pharma company
Acquisition of 2 key products and a secured warehouse from Norgine Ltd.
We have acquired Lionheart Pharmaceuticals, which is now Inphena Pain Research (IN PA RE). Very happy with this, and also to welcome Per Holm to our team
Inphena has signed a long term agreement with UNICEF for supply of products within opioid addiction through UNICEF. This follows an extensive due diligence process involving all of Inphenas business and suppliers.
Inphena has been working for some years with the Norwegian specialists within addiction treatment to set up a HAT program in Norway. The decision was taken by the government to implement a program, and Inphena was chosen to help and implement this program.
Inphena has expanded the product offering and competencies available by entering into a number of partnerships with individuals, organisations and associations. This enables us to execute competent training and offer a portfolio of products within the area of opioid addiction. In addition, our suply chain has been strengthened for our own developed products.
Want to learn more?
We look forward to meet you, and introduce you to patient and doctor driven healthcare solutions.
Connecting patients, doctors and treatments for the best possible solution.
We are based at the DTU Science Park near Copenhagen, Denmark, and at the Research park in Oslo, Norway, and are working internationally for the best possible solutions.
Our main warehouse location is in Valby, Copenhagen, which is a security level 60 warehouse for pharmaceuticals, approved for use by the Danish Medicines Agency.